We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · November 21, 2021

Individualized Dosing of Infliximab Reduces Variability in Exposure and Endoscopic Improvement Among Patients With Ulcerative Colitis

Pharmaceutics

 

Additional Info

Disclosure statements are available on the authors' profiles:

Pharmaceutics
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
Pharmaceutics 2021 Oct 06;13(10)1623, R Faelens, Z Wang, T Bouillon, P Declerck, M Ferrante, S Vermeire, E Dreesen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading